inclusion criteria: * 1. aged between 18 and 75 years, extremes included, male or female * 2. laboratory (rt-pcr) and clinical symptoms confirmed case of 2019-ncov pneumonia, according to the official guideline "pneumonia diagnosis and treatment scheme for novel coronavirus infection (trial version 5)" * 3. hospitalised with a new onset respiratory illness (≤7 days since illness onset) * 4. no family planning within six months, and agree to take effective contraceptive measures throughout the study and for at least 30 days after the final study drug dose * 5. must agree not to enroll in another study of an investigational agent prior to completion of day 30 of study * 6. informed consent form (icf) signed voluntarily

inclusion criteria: * 1. aged between 18 and 75 years, extremes included, male or female * 2. laboratory (rt-pcr) and clinical symptoms confirmed case of 2019-ncov pneumonia, according to the official guideline "pneumonia diagnosis and treatment scheme for novel coronavirus infection (trial version 5)" * 3. hospitalised with a new onset respiratory illness (≤7 days since illness onset) * 4. no family planning within six months, and agree to take effective contraceptive measures throughout the study and for at least 30 days after the final study drug dose * 5. must agree not to enroll in another study of an investigational agent prior to completion of day 30 of study * 6. informed consent form (icf) signed voluntarily

inclusion criteria: - 1. aged between 18 and 75 years, extremes included, male or female - 2. laboratory (rt-pcr) and clinical symptoms confirmed case of 2019-ncov pneumonia, according to the official guideline "pneumonia diagnosis and treatment scheme for novel coronavirus infection (trial version 5)" - 3. hospitalised with a new onset respiratory illness (≤7 days since illness onset) - 4. no family planning within six months, and agree to take effective contraceptive measures throughout the study and for at least 30 days after the final study drug dose - 5. must agree not to enroll in another study of an investigational agent prior to completion of day 30 of study - 6. informed consent form (icf) signed voluntarily

inclusion criteria: - 1. aged between 18 and 75 years, extremes included, male or female - 2. laboratory (rt-pcr) and clinical symptoms confirmed case of 2019-ncov pneumonia, according to the official guideline "pneumonia diagnosis and treatment scheme for novel coronavirus infection (trial version 5)" - 3. hospitalised with a new onset respiratory illness (≤7 days since illness onset) - 4. no family planning within six months, and agree to take effective contraceptive measures throughout the study and for at least 30 days after the final study drug dose - 5. must agree not to enroll in another study of an investigational agent prior to completion of day 30 of study - 6. informed consent form (icf) signed voluntarily